

# Specialty Guideline Management

## Corifact

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Corifact	coagulation Factor XIII concentrate [human]

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-Approved Indications<sup>1</sup>

Corifact is indicated in adult and pediatric patients with congenital Factor XIII deficiency for routine prophylactic treatment and peri-operative management of surgical bleeding.

#### Compendial Uses<sup>3,4</sup>

Acquired factor XIII deficiency

All other indications are considered experimental/investigational and not medically necessary.

# Coverage Criteria

## Factor XIII Deficiency<sup>1-4</sup>

Authorization of 12 months may be granted for treatment of factor XIII deficiency.

# Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when the member is experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds).

# References

1. Corifact [package insert]. Kankakee, IL: CSL Behring LLC; September 2020.
2. National Hemophilia Foundation. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System. Revised April 2024. MASAC Document #284. <https://www.bleeding.org/sites/default/files/document/files/MASAC-Products-Licensed.pdf>. Accessed October 15, 2024.
3. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. *Br J Haematol*. 2014;167(3):304-26.
4. AHFS DI (Adult and Pediatric) [database online]. Bethesda, MD. American Society of Health System Pharmacists, Inc. Electronic version. Updated October 2, 2024. Available with subscription. URL: <http://online.lexi.com/lco>. Accessed October 15, 2024.